SCHEMBL2033900

SCHEMBL2033900

CCC(CC)C(C)(c1ccc([N+](=O)[O-])cc1)P(=O)(O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
POLB P06746 1/20 0.47
AKR1C3 P42330 1/20 0.44
PTPRC P08575 1/20 0.43
CA1 P00915 3/20 0.41
CA12 O43570 2/20 0.41
MMP2 P08253 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP14 P50281 1/20 0.41
CA2 P00918 3/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
HSD11B1 P28845 1/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
HPGD P15428 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032757 0.78 FDPS (0.42) ALDH1A1ACHEHPGDMAPT
SCHEMBL28982292 0.76 CA2 (0.45) ALDH1A1POLBAKR1C3PTPRCCA1
SCHEMBL2637314 0.76 PTPRC (0.51) ALDH1A1POLBAKR1C3PTPRCCA1
SCHEMBL3230183 0.76 PTPRC (0.51) ALDH1A1POLBAKR1C3PTPRCCA1
SCHEMBL78562 0.75 ALDH1A1 (0.51) ALDH1A1POLBAKR1C3PTPRCCA1
SCHEMBL10683480 0.73 ALDH1A1 (0.52) ALDH1A1POLBAKR1C3CES2CES1
SCHEMBL9954932 0.71 ALDH1A1 (0.46) ALDH1A1POLBAKR1C3PTPRCKDM4E
SCHEMBL5897358 0.71 CA1 (0.50) POLBAKR1C3PTPRCCA1CA12
SCHEMBL2032900 0.71 ALDH1A1 (0.50) ALDH1A1POLBAKR1C3PTPRCCA1
SCHEMBL14487145 0.70 ALDH1A1 (0.45) ALDH1A1POLBCA1KDM4ECA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS ALDH1A1 1117/4885POLB 522/4885AKR1C3 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.